Group 1 - The company is guiding for 3.5% organic constant currency growth this year, following a 6% growth in 2025, indicating a diverse portfolio will drive this growth [1] - Core therapeutic areas include dermatology, parasitology, and pain management, with expectations for pain to return to growth in 2026, while parasitology is anticipated to lead growth this year due to increased competition in dermatology [2] - The diagnostics segment is performing well, and the livestock sector is highlighted as a bright spot, historically growing at 2% to 4% [3]